SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Anderson Kevin)) srt2:(2010-2014)
 

Search: (WFRF:(Anderson Kevin)) srt2:(2010-2014) > BCL2A1 is a lineage...

  • Haq, Rizwan (author)

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013-02-27
  • Proceedings of the National Academy of Sciences,2013

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:67f8ae65-7b36-4bf4-b007-1cabdb2406bf
  • https://lup.lub.lu.se/record/3760944URI
  • https://doi.org/10.1073/pnas.1205575110DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Although targeting oncogenic mutations in the BRAF serine/threonine kinase with small molecule inhibitors can lead to significant clinical responses in melanoma, it fails to eradicate tumors in nearly all patients. Successful therapy will be aided by identification of intrinsic mechanisms that protect tumor cells from death. Here, we used a bioinformatics approach to identify drug-able, "driver" oncogenes restricted to tumor versus normal tissues. Applying this method to 88 short-term melanoma cell cultures, we show that the antiapoptotic BCL2 family member BCL2A1 is recurrently amplified in similar to 30% of melanomas and is necessary for melanoma growth. BCL2A1 overexpression also promotes melanomagenesis of BRAF-immortalized melanocytes. We find that high-level expression of BCL2A1 is restricted to melanoma due to direct transcriptional control by the melanoma oncogene MITF. Although BRAF inhibitors lead to cell cycle arrest and modest apoptosis, we find that apoptosis is significantly enhanced by suppression of BCL2A1 in melanomas with BCL2A1 or MITF amplification. Moreover, we find that BCL2A1 expression is associated with poorer clinical responses to BRAF pathway inhibitors in melanoma patients. Cotreatment of melanomas with BRAF inhibitors and obatoclax, an inhibitor of BCL2A1 and other BCL2 family members, overcomes intrinsic resistance to BRAF inhibitors in BCL2A1-amplified cells in vitro and in vivo. These studies identify MITF-BCL2A1 as a lineage-specific oncogenic pathway in melanoma and underscore its role for improved response to BRAF-directed therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Yokoyama, Satoru (author)
  • Hawryluk, Elena B. (author)
  • Jönsson, Göran BLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-gjo (author)
  • Frederick, Dennie Tampers (author)
  • McHenry, Kevin (author)
  • Porter, Dale (author)
  • Tran, Thanh-Nga (author)
  • Love, Kevin T. (author)
  • Langer, Robert (author)
  • Anderson, Daniel G. (author)
  • Garraway, Levi A. (author)
  • Duncan, Lyn McDivitt (author)
  • Morton, Donald L. (author)
  • Hoon, Dave S. B. (author)
  • Wargo, Jennifer A. (author)
  • Song, Jun S. (author)
  • Fisher, David E. (author)
  • Bröstcancer-genetikSektion I (creator_code:org_t)

Related titles

  • In:Proceedings of the National Academy of Sciences: Proceedings of the National Academy of Sciences110:11, s. 4321-43261091-64900027-8424

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view